Advances in prevention of cervical cancer and other human papillomavirus-related diseases

Pediatric Infectious Disease Journal

Volumn 25, Issue 2 SUPPL., 2006, Pages

  Frazer, Ian H ^a   Cox, J Thomas ^b   Mayeaux Jr , Edward John ^c   Franco, Eduardo L ^d   Moscicki, Anna Barbara ^e   Palefsky, Joel M ^e   Ferris, Daron G ^f   Ferenczy, Alex S ^d   Villa, Luisa L ^g  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Louisiana State University School of Medicine Shreveport   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

Author keywords

Cervical cancer; Genital warts; Human papillomavirus

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L1; CARCINOGEN; UNCLASSIFIED DRUG; WART VIRUS VACCINE; VIRUS VACCINE;

ADOLESCENT HEALTH; ANTIBODY PRODUCING CELL; ANUS CANCER; ANUS DISEASE; ATTITUDE TO HEALTH; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CARCINOMA IN SITU; CAUSE OF DEATH; CLINICAL TRIAL; CONDOM; CONDYLOMA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ETHICS; HEALTH CARE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INJECTION SITE PAIN; MALIGNANT TRANSFORMATION; MORBIDITY; PAPANICOLAOU TEST; PARENTAL ATTITUDE; PATHOGENESIS; PENIS DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RELIGION; RISK; SEROCONVERSION; SEX DIFFERENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SOCIAL ASPECT; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS STRAIN; VIRUS TRANSMISSION; WART VIRUS; ADOLESCENT; ADULT; FEMALE; IMMUNOLOGY; MALE; PAPILLOMA VIRUS; REVIEW; RISK FACTOR; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; CONDOMS; FEMALE; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE DISEASES; PREVALENCE; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

EID: 33644983180     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000196485.86376.46     Document Type: Conference Paper

References (105)

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27.
2. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;31:14-19.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
6. IARC Working Group. IARC Monographs on the Evaluation Of Carcinogenic Risks to Humans: Human Papillomaviruses. Lyon, France: International Agency for Research on Cancer; 1995:64.
7. Report on Carcinogens. 11th ed. US Department of Health and Human Services, Public Health Services, National Toxicology Program:2004.
8. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6: 204.
9. Summary of the NIH Consensus Development Conference on Cervical Cancer. Oncology (Williston Park). 1997;11:672-674.
10. Division of STD Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants' Meeting, December 1999. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention:1999.
11. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866-1869.
12. The Kaiser Family Foundation and the American Social Health Association. Sexually Transmitted Diseases in America: How Many Cases and at What Cost? Menlo Park, CA: Kaiser Family Foundation; 1998.
13. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191: 114-120.
14. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92: 1500-1510.
15. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285: 1736-1745.
16. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177:361-367.
17. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol. 1999;37:3316-3322.
18. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3-8.
19. Strauss MJ, Khanna V, Koenig JD, et al. The cost of treating genital warts. Int J Dermatol. 1996;35:340-348.
20. Dupin N. Genital warts. Clin Dermatol. 2004;22:481-486.
21. Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001;137:337-341.
22. Herrero R. Chap. 7: Human papillomavirus and cancer of the upper aerodigestive tract. J Natl Cancer Inst Monogr. 2003:47-51.
23. Armstrong LR, Preston EJ, Reichert M, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis. 2000;31:107-109.
24. Baileff A. Cervical screening: patients' negative attitudes and experiences. Nurs Stand. 2000;14:35-37.
25. Harper DM. Why am I scared of HPV? CA Cancer J Clin. 2004;54: 245-247.
26. Persson G, Dahlof LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis. 1993;20:10-13.
27. Carter J, Auchincloss S, Sonoda Y, Krychman M. Cervical cancer: issues of sexuality and fertility. Oncology (Huntingt). 2003;17:1229-1234; discussion 1234-1226, 1239, 1242.
28. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis. 1999;26:S2-S7.
29. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10.
30. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-163.
31. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst. 1991; 83:997-1003.
32. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis. 2004;189:46-50.
33. Kahn JA, Slap GB, Huang B, et al. Comparison of adolescent and young adult self-collected and clinician-collected samples for human papillomavirus. Obstet Gynecol. 2004;103:952-959.
34. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182-192.
35. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-326.
36. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12:485-490.
37. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831-1836.
38. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.
39. Rousseau MC, Franco EL, Villa LL, et al. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev. 2000;9:469-476.
40. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92:464-474.
41. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749-1757.
42. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
43. Moscicki AB, Burt VG, Kanowitz S, Darragh T, Shiboski S. The significance of squamous metaplasia in the development of low-grade squamous intraepithelial lesions in young women. Cancer. 1999;85: 1139-1144.
44. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364: 1678-1683.
45. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry J, Darragh TM. High incidence of anal high-grade squamous intraepithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS. 1998;12:495-503.
46. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002;359:108-113.
47. Moscicki AB, Ellenberg JH, Crowley-Nowick P, Darragh TM, Xu J, Fahrat S. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis. 2004;190:1413-1421.
48. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397-1403.
49. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis. 2002;29:725-735.
50. Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers: decreasing prevalence with age despite continuously high sexual activity. Sex Transm Dis. 2000;27:438-445.
51. Hippelainen M, Syrjanen S, Koskela H, Pulkkinen J, Saarikoski S, Syrjanen K. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis. 1993;20:321-328.
52. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect. 1999;75:312-316.
53. Wang PD, Lin RS. Risk factors for cervical intraepithelial neoplasia in Taiwan. Gynecol Oncol. 1996;62:10-18.
54. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer. 2003;107:811-816.
55. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415-1423.
56. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
57. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005;97:577-586.
58. Spence A, Franco E. , Ferenczy A. The role of human papillomavirus in cancer. Am J Cancer. 2005;4:49-64.
59. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727-735.
60. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003;95:1336-1343.
61. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists: human papillomavirus. Obstet Gynecol. 2005;105: 905-918.
62. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
63. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
64. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004. Available at: http://seer.cancer.gov/csr/1975_2001/.
65. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 2004;190:37-45.
66. Gerberding J. Report to Congress: Prevention of Genital Human Papillomavirus Infection. Atlanta, GA: Centers for Disease Control and Prevention Department of Health and Human Services; 2004.
67. Svare EI, Kjaer SK, Worm AM, Osterlind A, Meijer CJ, van den Brule AJ. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect. 2002;78:215-218.
68. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105-1112.
69. Baldwin SB, Wallace DR, Papenfuss MR, et al. Human papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis. 2003;187:1064-1070.
70. Bosch FX, Castellsague X, Munoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst. 1996;88:1060-1067.
71. Graham S, Priore R, Graham M, Browne R, Burnett W, West D. Genital cancer in wives of penile cancer patients. Cancer. 1979;44: 1870-1874.
72. Smith PG, Kinlen LJ, White GC, Adelstein AM, Fox AJ. Mortality of wives of men dying with cancer of the penis. Br J Cancer. 1980;41: 422-428.
73. Castellsague X, Ghaffari A, Daniel RW, Bosch FX, Munoz N, Shah KV. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis. 1997;176:353-361.
74. Bleeker MC, Hogewoning CJ, Van Den Brule AJ, et al. Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol. 2002;47:351-357.
75. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138:453-459.
76. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis. 2004;190:2070-2076.
77. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst. 2005;97:896-905.
78. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822-1829.
79. Needle tips and the Hepatitis B Coalition News. In: Wexler D, ed. The Immunization Action Coalition. St. Paul, MN: IAC; 2004.
80. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991; 185:251-257.
81. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 1993;67: 315-322.
82. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004;22:2943-2952.
83. Ault KA, Giuliano AR, Edwards RP, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine. 2004;22:3004-3007.
84. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
85. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial: the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst. 2000;92:397-402.
86. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
87. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
88. Skjeldestad FE, FUTURE II Steering Committee. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Presented at: Infectious Diseases Society of America 43rd Annual Meeting; 2005, San Francisco, CA. Abstract LB-8a. Available at: http://www.idsociety.org/ Template.cfm?Section=Program2& CONTENTID=14108&TEMPLATE=/ ContentManagement/Content Display.cfm. Accessed November 8, 2005.
89. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48.
90. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615.
91. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-789.
92. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002;13:631-639.
93. Taira AV. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-1923.
94. Family Health International. Reproductive health of young adults. 2003. Available at: http://www.fhi.org/training/en/modules/ADOL/s1pg15. htm.
95. Gardasil™, Merck's investigational cervical cancer vaccine, produced high anti-HPV immune response in adolescents. Merck Press Release. Available at: http://www.merck.com/newsroom/press_releases/research_ and_development/2005_0519. html. Accessed August 12, 2005.
96. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis. 2000;27:49-52.
97. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004;58: 1405-1413.
98. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know? Health Educ Res. 2002;17: 706-714.
99. Holcomb B, Bailey JM, Crawford K, Ruffin MT. Adults' knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract. 2004;17:26-31.
100. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol. 2000;96:653-656.
101. Anhang R, Wright TCJ, Smock L, Goldie SJ. Women's desired information about human papillomavirus. Cancer. 2004;100:315-320.
102. Anhang R, Stryker JE, Wright TCJ, Goldie SJ. News media coverage of human papillomavirus. Cancer. 2004;100:308-314.
103. Anhang R, Goodman A, Goldie SJ. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin. 2004;54:248-259.
104. Mays RM, Zimet GD. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis. 2004;31:428-432.
105. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005; 23:2388-2394.